Program
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915
Also written as “JNJ-101556143” and “JNJ-101556143 Formulation 1”.
Its studies are mostly in Prostatic Neoplasms, led by Johnson & Johnson.
Drug pageAndrogen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Oct 26, 20263 company-led studies, 3 open or runningNext primary completion: Feb 14, 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 33 open or running | phase 3since Oct 26, 2026 | Jan 20, 2025 | Feb 14, 2028phase 3 · NCT07906717 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-6143 (HLD-0915)
, phase 1, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 20, 2025First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT06800313 · 190 planned · United States, United Kingdom
- Sep 16, 2026Phase 2 study in Prostatic NeoplasmsNCT07832292 · 100 planned · United States, Australia, China and more
- Oct 26, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedNCT07906717 · 400 planned · United States, Israel
Ahead
- Feb 14, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT07906717
- Aug 17, 2028Primary completion: phase 2 study in Prostatic NeoplasmsNCT06800313
- May 17, 2029Primary completion: phase 2 study in Prostatic NeoplasmsNCT07832292
TargetBeta
“An orally bioavailable bifunctional small molecule composed of an androgen receptor (AR)-binding moiety that is conjugated, via a linker, to a bromodomain-containing protein 4 (BRD4)-binding moiety, with potential antineoplastic activity. Upon oral administration of AR-targeting regulated induced…”NCIt, read by Claude
“An orally bioavailable bifunctional small molecule composed of an androgen receptor (AR)-binding moiety that is ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07906717Prostatic Neoplasms · United States, Israel | 3 | Recruiting | Feb 14, 2028 | 400 |
| NCT07832292Prostatic Neoplasms · United States, Australia, China and more | 2 | Recruiting | May 17, 2029 | 100 |
| NCT06800313Prostatic Neoplasms · United States, United Kingdom | 2 | Recruiting | Aug 17, 2028 | 190 |
How it is read
Names in the registry
- “JNJ-101556143”, 2 entries
- “JNJ-101556143 Formulation 1”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.